A mere 11 years ago, scientists Jennifer Doudna and Emmanuelle Charpentier unveiled CRISPR, a groundbreaking gene-editing method. The technology's transformative potential earned them the 2020 Nobel Prize in Chemistry.
Now, both the US and the UK have recognized this treatment method, approving the world's first gene-editing treatment. Doudna said that the rapid translation of this innovative therapy into practical medical applications is awe-inspiring, emphasizing the remarkable speed, safety, and effectiveness of its human application.
How Does the World's First Gene-Editing Treatment Work?
The approval of the world's first CRISPR-Cas9 gene-editing therapy, Casgevy, by the UK's regulator represents a groundbreaking achievement for Vertex Pharmaceuticals and CRISPR Therapeutics. This landmark approval sets the stage for anticipated US FDA approvals for sickle cell disease on December 8, 2023, and for β-thalassemia on March 30, 2024.
Despite the transformative potential of this therapy, initial implementation challenges loom, with limited healthcare infrastructure and patient reservations due to the novelty of the treatment.
The UK's decision to endorse Casgevy for sickle cell disease was influenced by its impressive success in eliminating severe vaso-occlusive crises in trial participants. However, the long-term impact on stroke reduction, organ damage, and life expectancy remains to be determined.
Casgevy, designed to induce fetal hemoglobin to compensate for the genetic mutation in sickle cell disease, targets patients' CD34+ hematopoietic stem cells. The therapy's administration is complex, involving blood transfusions, mobilization, apheresis, and myeloablative preconditioning, presenting logistical and toxic challenges.
Vertex aims to recruit 50 treatment centers in the US, primarily serving patients aged 12 and older with severe disease. However, challenges such as personnel requirements and the need for additional hiring may limit the initial scale of the Casgevy administration.
The broader adoption of gene-editing therapies faces obstacles, with survey results indicating that half of the medical centers planning to offer such therapies will need another year to prepare. The approval of Casgevy marks a pivotal moment in biotech, with the potential to revolutionize the treatment landscape for genetic diseases.
A New Hope That Comes With a Price
In trials led by Dr. Bhatia, approximately half of the patients' hemoglobin cells turned healthy, allowing them to avoid hospitalization and resume normal activities like attending school and work.
The new treatments present significant advancements for patients who have limited options, with hydroxyurea and bone marrow transplants being the primary alternatives, each carrying its own challenges and limitations.
Despite the transformative potential of CRISPR-based treatment, priced at $2.2 million, concerns linger over accessibility for many sickle cell patients. The complex and demanding nature of the treatments, coupled with the limited capabilities of many hospitals, poses physical and logistical challenges that may deter patients.
The breakthrough gene-editing therapies offer hope for a cure and preventing organ damage. Ongoing efforts aim to enhance accessibility, as Dr. Doudna stresses the need for broader availability across various illnesses.
Approval for patients aged 12 and older is crucial, allowing early intervention to prevent severe organ damage from sickle cell attacks, as emphasized by Dr. Mapara. This expands the potential reach of therapies, providing a proactive solution for younger patients.
RELATED ARTICLE: Gene Editing Startup Pairwise Introduces Food Made With CRISPR Technology Making Vegetables More Palatable
Check out more news and information on CRISPR in Science Times.
